Alkermes plc (NASDAQ:ALKS) EVP Sells $290,461.50 in Stock

Alkermes plc (NASDAQ:ALKS) EVP Craig C. Hopkinson sold 9,221 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $31.50, for a total value of $290,461.50. Following the completion of the transaction, the executive vice president now owns 59,730 shares of the company’s stock, valued at $1,881,495. The trade was a 13.37 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Alkermes Trading Up 0.4 %

Shares of ALKS traded up $0.13 on Thursday, hitting $31.19. 1,747,926 shares of the stock traded hands, compared to its average volume of 1,813,188. The firm has a market capitalization of $5.05 billion, a P/E ratio of 15.93, a P/E/G ratio of 0.98 and a beta of 0.49. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. Alkermes plc has a 1 year low of $22.90 and a 1 year high of $32.88. The stock’s 50 day moving average is $28.17 and its two-hundred day moving average is $26.66.

Institutional Investors Weigh In On Alkermes

Several hedge funds have recently made changes to their positions in the business. V Square Quantitative Management LLC purchased a new position in Alkermes during the third quarter worth about $29,000. Signaturefd LLC lifted its holdings in shares of Alkermes by 51.2% during the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock worth $34,000 after acquiring an additional 480 shares during the period. Hexagon Capital Partners LLC grew its holdings in Alkermes by 3,841.0% in the second quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock valued at $37,000 after purchasing an additional 1,498 shares during the period. GAMMA Investing LLC increased its position in Alkermes by 44.4% during the second quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after purchasing an additional 703 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alkermes during the 2nd quarter valued at $116,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Analysts Set New Price Targets

ALKS has been the subject of a number of research analyst reports. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and increased their price target for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. Mizuho lifted their price target on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Piper Sandler restated an “overweight” rating and issued a $37.00 price target (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. Cantor Fitzgerald reduced their price objective on Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Finally, HC Wainwright reissued a “neutral” rating and issued a $37.00 target price on shares of Alkermes in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.42.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.